Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Acute Ischemic Stroke (STARS)
NCT07030621Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in ischemic stroke, sponsored by Renji Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07030621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030621.